Dear Innitius Community,
Preterm birth remains one of the biggest challenges in maternal healthcare, yet it is often misunderstood—even within the medical community. Despite advances in obstetrics, traditional methods for predicting preterm birth remain unreliable, leading to unnecessary interventions or missed opportunities for early treatment.
The consequences of inaccurate diagnosis are significant: unnecessary hospitalizations, increased healthcare costs, and most importantly, missed chances to provide the right care at the right time. At Innitius, we are committed to challenging outdated assumptions and providing data-driven solutions that improve pregnancy outcomes. Let’s debunk some of the most common myths surrounding preterm birth prediction.
Myth #1: Preterm Birth is Always Predictable with Current Methods
Reality: Traditional diagnostic tools, including manual cervical exams, ultrasounds, and biochemical markers, are often inaccurate. Studies show that up to 50% of preterm labor diagnoses are incorrect, leading to either unnecessary hospitalizations or delayed interventions when they are truly needed. CerviSense, our patented torsional wave device, is changing this. By quantifying cervical softness, it offers an objective, real-time assessment that significantly improves accuracy over traditional methods.
Myth #2: Ultrasound and Biomarkers are Enough for Accurate Prediction
Reality: While ultrasound and biomarkers like fetal fibronectin (fFN) and phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) are commonly used, their predictive power is limited:
- fFN sensitivity is only 20%, meaning most preterm labor cases go undetected.
- Current methods have a high false positive rate, leading to unnecessary medical interventions and increased healthcare costs.
Cervical consistency has been identified as the most predictive factor, yet until now, there has been no way to measure it reliably.
Myth #3: Preterm Birth Cannot Be Prevented
Reality: While not all cases can be prevented, early detection is key to improving outcomes. More accurate diagnostics allow for:
- Timely administration of medications to improve fetal
development. - Better decision-making on hospital admissions, reducing unnecessary bed occupancy.
The Future of Preterm Birth Prediction
At Innitius, we are pioneering a new standard in obstetric diagnostics. CerviSense has been clinically validated in 10 hospitals—including Vall d’Hebron, La Fe, and Virgen del Rocío—and has demonstrated:
- 71% sensitivity vs. 20% in traditional biomarkers.
- 95% specificity vs. 89%, reducing false positives.
- Faster, real-time assessments, optimizing clinical workflows.
By integrating AI-driven analysis and real-time data, CerviSense is eliminating guesswork and providing actionable insights for physicians.
Let’s Change the Conversation
Breaking these myths is critical to improving maternal and neonatal outcomes. It’s time to embrace scientific advancements that provide clarity, accuracy, and better decision-making in obstetrics.
We invite you to explore how CerviSense is transforming preterm birth prediction. If you’re a healthcare professional, investor, or advocate for maternal health, let’s connect and discuss how we can shape the future of obstetric care together.
